drugset / Trial / NCT00861497

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

NCT00861497 ↗

Phase 3 Terminated 11 enrolled H. Lundbeck A/S Solvay Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate. A further purpose is to investigate the safety and side-effects of bifeprunox during long-term treatment.

Timeline

Start
2006-01
Primary completion
2008-01
Completion
2009-07

Outcome

Outcome not reported

Stopped: “The study stopped after been paused (the patients were switched in the meantime)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifeprunox Small molecule 20 mg —
Subject Bifeprunox Small molecule 30 mg —
Subject Bifeprunox Small molecule 40 mg —

Indications